Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO +7.48%35 Equity-to-Asset is 0.91 as of Mar. 2026, which is 2% above its 10-year median of 0.89. GuruFocus rates OSTO:ICO with a GF Score™ of 35/100 and a GF Value™ of kr0.26 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Iconovo AB ranks better than 94.36% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Iconovo AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr157.77 Mil. Iconovo AB's Total Assets for the quarter that ended in Mar. 2026 was kr173.25 Mil.
Therefore, Iconovo AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.91.
The historical rank and industry rank for Iconovo AB's Equity-to-Asset or its related term are showing as below:
OSTO:ICO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.89 Max: 0.96
Current: 0.91
During the past 10 years, the highest Equity to Asset Ratio of Iconovo AB was 0.96. The lowest was 0.43. And the median was 0.89.
OSTO:ICO's Equity-to-Asset is ranked better than 94.36% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs OSTO:ICO: 0.91
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Iconovo AB Equity-to-Asset Related Terms
Iconovo AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Iconovo AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ICO vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Iconovo AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Iconovo AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Iconovo AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iconovo AB (OSTO:ICO) has a Equity-to-Asset of 0.91 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Iconovo AB and its competitors. This is near median its historical median of 0.89. Over the past decade, Iconovo AB's Equity-to-Asset has ranged from 0.43 to 0.96. According to the industry distribution chart, Iconovo AB ranks #48 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 5.6%.
Is Iconovo AB's Equity-to-Asset too high?
Iconovo AB's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.96. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Iconovo AB's value of 0.91 is 42.2% above this industry median. Based on the distribution chart, Iconovo AB ranks #48 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Iconovo AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #48 out of 851 companies for Equity-to-Asset. This places Iconovo AB in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Iconovo AB's value of 0.91 is 42.2% above this benchmark. Historically, Iconovo AB's own Equity-to-Asset has ranged from 0.43 to 0.96 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.64, Iconovo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iconovo AB's current Equity-to-Asset of 0.91 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Iconovo AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.26, compared to a current price of kr1.15 — trading 342.3% above its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.89 and 42.2% above the Medical Devices & Instruments industry median of 0.64. Iconovo AB's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Equity-to-Asset is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr1.15 is trading 342.3% above its estimated GF Value™ of kr0.26.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
Equity-to-Asset: 0.91 (near median its 10-year median of 0.89)
GF Value™: kr0.26 vs. price of kr1.15 (342.3% above fair value)
Industry Position: 42.2% above the Medical Devices & Instruments median (#48 of 851)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
35GF Score
Get the complete analysis for OSTO:ICO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
